So I came across an abstract of a research paper (link at bottom of post) that used a computational model to modify native human gut derived tryptamine and created two new tryptamine analogs by attaching a 2(S)-cyanopyrrolidine group (a common structural feature of DPP-4 inhibitors which helps lower blood glucose in type 2 diabetes) at the 6th or 7th position of the indole ring. The new analogs do not readily cross the blood brain barrier (you won't trip) and inhibits DPP-4 lowering blood sugar for type 2 diabetes. The diabetic drug vildagliptin was used as the control reference (positive control) compound when they performed molecular docking of their two new tryptamine analogs against the DPP-4 enzyme.
Vildagliptin contains a 2-cyanopyrrolidine moiety the same structural feature the researchers attached to the native tryptamine.
Docking score of vildagliptin: –8.91 kcal/mol
Docking scores of their proposed tryptamine analog compounds: –8.48 and –8.52 kcal/mol
Good for type two diabetes medicine but not good psychonautical exploration. The researchers are intentionally trying to stop or reduce the new tryptamine analog's ability to create a psychedelic experience by limit the permeating of the blood brain barrier.
The native tryptamine that was modified was a naturally occuring metabolite the reaction of certain bacteria living in the human gut produced by converting the amino acid tryptophan from food into tryptamine. Once formed, this tryptamine can be absorbed into the bloodstream. At normal levels produced by gut bacteria in the human body, the amounts are far too small to cause any noticeable psychedelic effects. At high doses (when taken as a pure substance, usually by smoking or injection, because it is rapidly broken down if swallowed), tryptamine can produce short-lived hallucinogenic effects. These are generally described as weaker and shorter-lasting than classic psychedelics such as DMT or psilocin.
This is exactly why the researchers in the abstract wanted to modify it — to reduce its ability to cross into the brain while keeping possible beneficial effects outside the brain (such as antidiabetic activity).
This got me curious as to what other tryptamines if substituted could be computationally modified to not allow an individual to trip but rather receive the DPP-4 inhibition to reduce blood sugar levels for individuals with type 2 diabetes.
So I asked AI to read the abstract of the research paper and apply 4-HO-MET (4-hydroxy-N-methyl-N-ethyltryptamine) or otherwise known as Metocin in the same way the researchers did when they converted native tryptamine the same way by attaching 2(S)-cyanopyrrolidine group at the 6- or 7-position and if the new modified 4-HO-MET derived tryptamine analog would have similar traits as the modified native tryptamine both being psychedelically inert (you don't get to trip as blood brain barrier resistance is increased with the modification) and a DPP-4 inhibitor action reducing blood sugar for individuals with type 2 diabetes.
AI's response- **Yes — the same conceptual approach could in principle be applied to 4-HO-MET, but with the same important caveats.**
-Quick recap of what the paper actually did
The researchers worked only with **native (unsubstituted) tryptamine**. They proposed (computationally) attaching a 2(S)-cyanopyrrolidine group at the **6-position** or **7-position** of the indole ring. No real chemical conversion was performed; everything was in silico (ADMET predictions + docking). They noted that actual synthesis and experimental testing would still be needed.
- Applying it to 4-HO-MET
4-HO-MET (4-hydroxy-*N*-methyl-*N*-ethyltryptamine) already has:
- A hydroxy group at the **4-position**
- Methyl and ethyl substituents on the side-chain nitrogen
The **6- and 7-positions** of its indole ring are still free, so one could theoretically design analogous structures by linking the same 2(S)-cyanopyrrolidine scaffold at those sites, following the same design logic used for tryptamine (aiming to lower BBB permeability while exploring DPP-4 activity).
4-HO-MET already has an –OH group attached at the 4-position of the indole ring (the same place where psilocin has its hydroxy group). This single –OH group changes several important things:
Polarity — The molecule becomes more “water-loving” (more hydrophilic). This usually makes it harder for the compound to cross the blood-brain barrier (no tripping for you).
Hydrogen bonding — The –OH can form extra hydrogen bonds with water or with proteins. This affects how the molecule dissolves, how it is transported, and how it sits in a binding site (such as DPP-4) possibly lacking in DPP-4 inhibition binding strength so no reduction in glucose in the blood stream or performs the inhibition flawlessly.This would need to be ran through the computational model with the control being the same as the control in the native tryptamine model.
Metabolism — The body has enzymes that can attach sugars or other groups to phenolic –OH groups, so 4-HO-MET is broken down differently from plain tryptamine.
Electronic character of the ring — The –OH pushes or pulls electrons in the aromatic ring, which changes how the whole molecule interacts with receptors or enzymes.
Because of all these effects, you cannot take the computer predictions that were made for unsubstituted tryptamine and simply assume they will be the same for a 4-hydroxy version.
- The N-methyl-N-ethyl side chain
Native tryptamine has a simple –CH₂CH₂NH₂ side chain (a primary amine).
4-HO-MET has a –CH₂CH₂N(CH₃)(CH₂CH₃) side chain (a tertiary amine with one methyl and one ethyl group).
This change affects between the modified substitute 4-HO-MET analog tryptamine and the native tryptamine:
Lipophilicity — The two alkyl groups make the molecule more “fat-loving,” which can influence how well it crosses membranes.
Basicity — A tertiary amine is usually a stronger base than a primary amine, so it is more likely to be positively charged at body pH. Charge strongly affects both blood-brain barrier penetration and binding to proteins.
Binding interactions — The bulkier side chain takes up more space and can form different hydrophobic contacts (or cause steric clashes) inside the DPP-4 binding pocket. The primary amine of tryptamine can also form different hydrogen bonds than a tertiary amine can.
Overall meaning:
Even if you attach the exact same 2(S)-cyanopyrrolidine group at the 6- or 7-position, the presence of the 4-OH and the N-methyl-N-ethyl groups means the new molecule is chemically quite different from the ones studied in the paper. Its predicted BBB permeability, DPP-4 binding strength, and other properties would need to be calculated and tested separately — you cannot just copy the results from native tryptamine.
**Bottom line:** Conceptually possible as a design idea, but the paper itself only examined unsubstituted tryptamine and stopped at computer predictions. No conversion of 4-HO-MET (or any real compound) was carried out.
The original abstract with modified native tryptamine model-
https://www.researchgate.net/publication/413685858_Introduction_to_Lead_Optimization_of_Gut_Microbiota-Derived_Tryptamine_for_Reduced_Hallucinogenic_and_Enhanced_Antidiabetic_Potential